Why the study?
Cardiovascular disease remains a leading cause of global morbidity and mortality, necessitating the search for novel therapeutics such as the cardioprotective gaseous signaling molecule hydrogen sulfide.
Does hydrogen sulfide have therapeutic potential in cardiovascular diseases?
Does hydrogen sulfide have therapeutic potential in cardiovascular diseases?
Hydrogen sulfide is an endogenously produced gasotransmitter with significant cardioprotective properties and therapeutic potential across multiple cardiovascular diseases.
Cardiovascular disease (CVD) stands as one of the leading causes of morbidity and mortality worldwide, and the continued search for novel therapeutics is vital for addressing this global health challenge. Over the past decade, hydrogen sulfide (H₂S) has garnered significant attention in the field of medical research, as it has been proven to be a cardioprotective gaseous signaling molecule. It joins nitric oxide and carbon monoxide as endogenously produced gasotransmitters. As for its mechanism, H₂S functions through the posttranslational addition of a sulfur group to cysteine residues on target proteins in a process called sulfhydration. As a result, the observed physiological effects of H₂S can include vasodilation, anti-apoptosis, anti-inflammation, antioxidant effects, and regulation of ion channels. Various studies have observed the cardioprotective benefits of H₂S in diseases such as myocardial infarction, ischemia-reperfusion injury, cardiac remodeling, heart failure, arrhythmia, and atherosclerosis. In this review, we discuss the mechanisms and therapeutic potential of H₂S in various CVDs.
No takes yet. Share an insight, caveat, or question.
Islam et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: